Gut microbiota perturbations in response to SARS-CoV-2 and survival outcomes in patients with cancer.
Abstract
178 Background: The gut microbiota plays a critical role in immune function, but in diseases such as cancer, dysbiosis may increase vulnerability to external factors like viral infections. In this study, we investigated the impact of gut microbiota in relation to SARS-CoV-2 infection in cancer patients. Methods: Stools collected at recruitment underwent shotgun metagenomic sequencing and inflammatory cytokine profiling using ELISA. Taxonomy data were correlated with infection status, disease severity and mortality. All analyses were adjusted for age, sex, smoking status, tumor type, stage at COVID-19 diagnosis, comorbidities, and vaccination. Results: A total of 195 patients with solid tumors (colon=60, breast=43, miscellaneous=92) were prospectively enrolled. SARS-CoV-2-infected cancer patients (n=98) showed reduced α-diversity (Shannon and Chao1 indexes, p=0.002) and a distinct microbial composition (p=0.004) with Enterococcus spp. enrichment ( E.A avium, E.B faecium, E. faecalis ) compared to non-infected patients (n=97). Hospitalized patients due to severe SARS-CoV-2 infection exhibited depletion of several commensal species including Eubacterium spp. and Lachnospira spp., which were positively correlated with gut immune response assessed by stool cytokines. In an adjusted logistic model of overall survival, SARS-CoV-2 infection was significantly associated to higher all-cause mortality (OR=4.56; 95%CI: 2.16–10.03; p<0.0001). Forty-four taxa (32 depleted and 12 enriched) could differentiate deceased vs alive patients, independently of SARS-CoV-2 infection status. These severity-related microbiota composition correlated with the magnitude of systemic inflammatory response with increased concentration of blood C reactive protein, lactate dehydrogenase, and lymphopenia with depletion of commensals. Conclusions: Depletion of protective gut commensals and enrichment of pathogens may impair immune sensing and response to viral infections ultimately contributing to the hyperinflammatory state and lymphodepletion linked with severe disease and mortality. The lack of cohort-specific taxa suggests that the higher mortality induced by SARS-CoV-2 in cancer patients may be driven by a pre-existing dysbiosis.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (20)
Alba Santiago Badenas
Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Nuria Moragas Garcia
Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Barcelona, Spain
Fiorella Ruiz-Pace
Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Mireia Obon Santacana
Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Barcelona, Spain
Iosune Baraibar
5Vall d'Hebron Institute of Oncology (VHIO), Medical Oncology Department, Vall d'Hebron University Hospital, University Autonoma of Barcelona (UAB), Barcelona, Spain
Maria Vieito Villar
Vall d'Hebron Institute of Oncology, Barcelona, Spain
Ariadna Garcia
Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Laura Boleda Monferrer
Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Mafalda Oliveira
Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona
Andri Papakonstantinou
Nuria Mulet Margalef
Medical Oncology Department, Catalan Institute of Oncology (ICO), L´Hospitalet De Llobregat, Barcelona, Spain
Paula Gubern Prieto
Medical Oncology Department, Catalan Institute of Oncology (ICO), Barcelona, Spain
Elisabet Guino
Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Barcelona, Spain
Stefania Napoli
Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Juan Aguilar-Company
Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Cristina Saura Manich
Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Elena Garralda
Elena Elez
Vall d’Hebron Hospital Campus, Barcelona
Víctor Moreno
Paolo Nuciforo